Paul G Matz, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 6600 E 2nd St, Casper, WY 82609 Phone: 307-266-4000 Fax: 307-233-0266 |
Dr. Albert Victor Metz Jr., Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 6800 S Poplar St, Casper, WY 82601 Phone: 307-265-1468 Fax: 307-265-5806 |
Robert A Narotzky, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 6600 E 2nd St, Casper, WY 82609 Phone: 307-266-4000 Fax: 307-266-4545 |
Dr. Wayne Lee Warren Jr., MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 419 S Washington St Ste 201, Casper, WY 82601 Phone: 307-233-0250 Fax: 307-237-5421 |
Thomas A Kopitnik Jr., MD FACS Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 6600 E 2nd St, Casper, WY 82609 Phone: 307-266-4000 Fax: 307-266-4545 |
News Archive
Bill and Hillary Clinton are off saving the world, he through his global foundation and she via the State Department. But their presence looms over the health care debate as surely as if they were running the White House. Their epic failure to pass reform in 1994 has become the defining object lesson in how to botch health care legislation-a lesson President Obama has obviously taken to heart. Push for reform right away; let Congress hash out the details; and, above all, don't threaten people's current insurance arrangements. You can sum up Obama's strategy for health reform as "WWCD": What Wouldn't the Clintons Do.
The International AIDS Vaccine Initiative's (IAVI) January 2007 Annual Issue of VAX, an editorially independent bulletin on AIDS vaccine research published by IAVI, reports that 13 new preventive AIDS vaccine trials were initiated in eight countries around the world in 2006.
Today's early morning highlights from the major news organizations, including reports about the Obama administration and Pennsylvania reaching an agreement to expand Medicaid in that state.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).
› Verified 4 days ago